Polatuzumab Vedotin Combined with Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone (G-CHP) for Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Preliminary Results of a Phase Ib/II Dose-Escalation Study

被引：2

作者：

Forero-Torres, Andres ^{[1
]}

Kolibaba, Kathryn S. ^{[2
]}

Lamy, Thierry ^{[3
]}

Jones, Surai ^{[4
]}

Lee, Calvin ^{[4
]}

Sharman, Jeff ^{[5
,6
]}

机构：

[1] Univ Alabama Birmingham, Dept Med, Birmingham, AL USA

[2] Compass Oncol, Portland, OR USA

[3] INSERM U917 Univ Hosp Rennes, Dept Hematol, Rennes, France

[4] Genentech Inc, South San Francisco, CA USA

[5] McKesson Specialty US Oncol Res, The Woodlands, TX USA

[6] Willamette Valley Canc Inst & Res Ctr, Springfield, OR USA

来源：

关键词：

D O I：

10.1182/blood.V128.22.1856.1856

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1856

引用

页数：7